secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001104659-26-036818
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech subsidiary Cyprium closes PRV sale for $205M; Fortress expects over $100M
--------------------------------------------------------------------------------

- Cyprium sold Rare Pediatric Disease Priority Review Voucher for $205M gross proceeds.
- Fortress (80.4% owner) expects over $100M from dividends and intercompany agreements.
- PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on Jan 12, 2026.
- Cyprium redeemed all outstanding 9.375% Perpetual Preferred Stock in connection with sale.
- Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to ~$128M in milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/0001104659-26-036818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/fbio-20260330x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-036818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer